{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0006105\nAge: 66\nGender: Male\nSample ID: P-0006105-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Lung Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 40.0%\n=============\nDNA Variants:\nCTNNB1 c.109T>G (p.S37A) - in 14.00% of 551 reads\nEGFR c.2369C>T (p.T790M) - in 12.00% of 1101 reads\nEGFR c.2236_2250del (p.E746_A750del) - in 21.00% of 850 reads\nFLT4 c.156-1G>A (p.X52_splice) - in 14.00% of 480 reads\nPTEN c.1001A>G (p.N334S) - in 20.00% of 263 reads\nCNA Data:\nCDKN2B - Homozygous Deletion\nCDKN2A - Homozygous Deletion\nCDKN2Ap14ARF - Homozygous Deletion\nCDKN2Ap16INK4A - Homozygous Deletion\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Lung Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Osimertinib\",\n    \"Prior Treatment or Resistance Status\": \"T790M mutation indicating resistance to first-generation EGFR inhibitors\",\n    \"Genomic Features\": \"EGFR c.2369C>T (p.T790M), EGFR c.2236_2250del (p.E746_A750del)\",\n    \"FDA-approval status\": \"Approved for T790M-positive non-small cell lung cancer after progression on EGFR inhibitors\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209436s000lbl.pdf\"\n  }\n}"
}